Date: 2015-01-05
Type of information: Nomination
Compound:
Company: Isis Pharmaceuticals (USA - CA)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details:
Financial terms:
Latest news: * On January 5, 2015, Isis Pharmaceuticals announced that Sarah Boyce has joined the company as chief business officer. In this newly created position, Ms. Boyce will provide strategic leadership from a commercial background and lead Isis\' corporate development activities, including corporate communications, business development, patient advocacy, competitive intelligence and alliance management. Ms. Boyce will also serve as a member of Isis\' executive leadership team. Prior to joining Isis as chief business officer, Ms. Boyce was vice president, head of international business strategy and operations at Forest Laboratories, Inc. where she was recruited to lead the launch, development and expansion of their international efforts for their pharmaceutical and consumer health business. Prior to Forest, Ms. Boyce served on the Alexion management team and led the global launch of a new therapy area for the company. Ms. Boyce spent 10 years working at Novartis; first in the oncology business unit of their pharmaceuticals division and then as vice president, global program head in the pediatrics and specialty vaccine business for the vaccine and diagnostics division. Prior to her tenure at Novartis, Ms. Boyce worked at Bayer Pharmaceuticals as global strategic marketing manager and at Roche, where she led the launches of multiple drugs in the UK. Ms. Boyce has a Bachelor of Science degree in microbiology from the University of Manchester, England.
